Skip to main content
. 2023 Jan 30;239(3):362–367. doi: 10.1159/000528968

Table 1.

Characteristics of included patients

Tetracyclines, n = 180 Clindamycin and rifampicin, n = 103 p value
Patient characteristics
 Gender
  Females, n (%) 106 (58.9) 56 (54.4) 0.533
 Age, median [IQR] 37 [26–46] 36 [27–45] 0.917
  Missing, n 0 1
 Age of onset, median [IQR] 21 [15–30] 21 [16–28] 0.854
  Missing, n 3 0
 Disease duration, median [IQR] 10 [6–19] 10 [5–17] 0.415
  Missing, n 3 1
 BMI, mean (SD) 29.81 (6.1) 29.21 (6.2) 0.428
  Missing, n 6 0
 Current smoker, n (%) 110 (61.8) 56 (56.6) 0.443
  Missing, n 2 4
 Family history of HS, n (%) 58 (34.3) 34 (35.1) 1.000
  Missing, n 11 6
PROMs
 DLQI, mean (SD) 13.3 (7.5) 15.1 (7.9) 0.071
  Missing, n 8 7
 NRS Pain, median [IQR] 6 [4–8] 7 [5–8] 0.005
  Missing, n 7 3
 NRS Pruritus, median [IQR] 3 [0–6] 4 [0–7] 0.204
  Missing, n 13 8
Physician scores
 Inflammatory nodules, median [IQR] 3.5 [1.0–6.0] 4 [2–9] 0.029
 Abscesses, median [IQR] 0.0 [0.0–2.0] 0 [0–2] 0.975
 Draining sinus tracts, median [IQR]
 Hurley stage 1.0 [0.0–2.0] 1 [0–4] 0.003
  Stage I, n (%) 54 (30.2) 14 (13.6) 0.004
  Stage II, n (%) 90 (50.3) 58 (56.3)
  Stage III, n (%) 35 (19.5) 31 (30.1)
  Missing, n 1 0
 IHS4, median [IQR] 9.0 [5.0–18.5] 13.0 [6.0–27.0] 0.019
  Mild, n (%) 29 (16.1) 8 (7.8) 0.032
  Moderate, n (%) 77 (42.8) 38 (36.9)
  Severe, n (%) 74 (41.1) 57 (55.3)